Literature DB >> 27777973

Systems biology analysis reveals role of MDM2 in diabetic nephropathy.

Rintaro Saito1,2,3, Anaïs Rocanin-Arjo4, Young-Hyun You2,3, Manjula Darshi1,3, Benjamin Van Espen1,3, Satoshi Miyamoto2,3, Jessica Pham2,3, Minya Pu1,5, Simone Romoli4, Loki Natarajan1,5, Wenjun Ju6, Matthias Kretzler6, Robert Nelson7, Keiichiro Ono3, Dana Thomasova4, Shrikant R Mulay4, Trey Ideker3, Vivette D'Agati8, Ergin Beyret9, Juan Carlos Izpisua Belmonte9, Hans Joachim Anders4, Kumar Sharma1,2,3,10.   

Abstract

To derive new insights in diabetic complications, we integrated publicly available human protein-protein interaction (PPI) networks with global metabolic networks using metabolomic data from patients with diabetic nephropathy. We focused on the participating proteins in the network that were computationally predicted to connect the urine metabolites. MDM2 had the highest significant number of PPI connections. As validation, significant downregulation of MDM2 gene expression was found in both glomerular and tubulointerstitial compartments of kidney biopsy tissue from 2 independent cohorts of patients with diabetic nephropathy. In diabetic mice, chemical inhibition of MDM2 with Nutlin-3a led to reduction in the number of podocytes, increased blood urea nitrogen, and increased mortality. Addition of Nutlin-3a decreased WT1+ cells in embryonic kidneys. Both podocyte- and tubule-specific MDM2-knockout mice exhibited severe glomerular and tubular dysfunction, respectively. Interestingly, the only 2 metabolites that were reduced in both podocyte and tubule-specific MDM2-knockout mice were 3-methylcrotonylglycine and uracil, both of which were also reduced in human diabetic kidney disease. Thus, our bioinformatics tool combined with multi-omics studies identified an important functional role for MDM2 in glomeruli and tubules of the diabetic nephropathic kidney and links MDM2 to a reduction in 2 key metabolite biomarkers.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27777973      PMCID: PMC5070958          DOI: 10.1172/jci.insight.87877

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  48 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Genome-Wide Analysis of Wilms' Tumor 1-Controlled Gene Expression in Podocytes Reveals Key Regulatory Mechanisms.

Authors:  Martin Kann; Sandrine Ettou; Youngsook L Jung; Maximilian O Lenz; Mary E Taglienti; Peter J Park; Bernhard Schermer; Thomas Benzing; Jordan A Kreidberg
Journal:  J Am Soc Nephrol       Date:  2015-01-30       Impact factor: 10.121

3.  Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy.

Authors:  Akiyoshi Hirayama; Eitaro Nakashima; Masahiro Sugimoto; Shin-ichi Akiyama; Waichi Sato; Shoichi Maruyama; Seiichi Matsuo; Masaru Tomita; Yukio Yuzawa; Tomoyoshi Soga
Journal:  Anal Bioanal Chem       Date:  2012-09-29       Impact factor: 4.142

4.  Mdm2 is required for maintenance of the nephrogenic niche.

Authors:  Sylvia A Hilliard; Xiao Yao; Samir S El-Dahr
Journal:  Dev Biol       Date:  2014-01-17       Impact factor: 3.582

Review 5.  Branch chain amino acids: biomarkers of health and disease.

Authors:  Bryan C Batch; Kristen Hyland; Laura P Svetkey
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2014-01       Impact factor: 4.294

Review 6.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

7.  Diabetes and renal tubular cell apoptosis.

Authors:  Samy L Habib
Journal:  World J Diabetes       Date:  2013-04-15

8.  GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy.

Authors:  Mengjie Li; Xufang Wang; Jiye Aa; Weisong Qin; Weibin Zha; Yongchun Ge; Linsheng Liu; Tian Zheng; Bei Cao; Jian Shi; Chunyan Zhao; Xinwen Wang; Xiaoyi Yu; Guangji Wang; Zhihong Liu
Journal:  Am J Physiol Renal Physiol       Date:  2013-03-06

9.  Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease.

Authors:  Kumar Sharma; Bethany Karl; Anna V Mathew; Jon A Gangoiti; Christina L Wassel; Rintaro Saito; Minya Pu; Shoba Sharma; Young-Hyun You; Lin Wang; Maggie Diamond-Stanic; Maja T Lindenmeyer; Carol Forsblom; Wei Wu; Joachim H Ix; Trey Ideker; Jeffrey B Kopp; Sanjay K Nigam; Clemens D Cohen; Per-Henrik Groop; Bruce A Barshop; Loki Natarajan; William L Nyhan; Robert K Naviaux
Journal:  J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 10.121

10.  Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.

Authors:  Monika A Niewczas; Tammy L Sirich; Anna V Mathew; Jan Skupien; Robert P Mohney; James H Warram; Adam Smiles; Xiaoping Huang; Walker Walker; Jaeman Byun; Edward D Karoly; Elizabeth M Kensicki; Gerard T Berry; Joseph V Bonventre; Subramaniam Pennathur; Timothy W Meyer; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2014-01-15       Impact factor: 10.612

View more
  16 in total

1.  A metabolite-GWAS (mGWAS) approach to unveil chronic kidney disease progression.

Authors:  Guanshi Zhang; Rintaro Saito; Kumar Sharma
Journal:  Kidney Int       Date:  2017-06       Impact factor: 10.612

Review 2.  Emerging role of tumor suppressor p53 in acute and chronic kidney diseases.

Authors:  Jessica M Overstreet; Cody C Gifford; Jiaqi Tang; Paul J Higgins; Rohan Samarakoon
Journal:  Cell Mol Life Sci       Date:  2022-08-09       Impact factor: 9.207

Review 3.  The Promise of Systems Biology for Diabetic Kidney Disease.

Authors:  Frank C Brosius; Wenjun Ju
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

Review 4.  Mitochondrial dysfunction in diabetic kidney disease.

Authors:  Josephine M Forbes; David R Thorburn
Journal:  Nat Rev Nephrol       Date:  2018-02-19       Impact factor: 28.314

Review 5.  The Warburg Effect in Diabetic Kidney Disease.

Authors:  Guanshi Zhang; Manjula Darshi; Kumar Sharma
Journal:  Semin Nephrol       Date:  2018-03       Impact factor: 5.299

Review 6.  Targeting MDM2 for novel molecular therapy: Beyond oncology.

Authors:  Wei Wang; Jiang-Jiang Qin; Mehrdad Rajaei; Xin Li; Xiaoyi Yu; Courtney Hunt; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2019-10-06       Impact factor: 12.944

Review 7.  TGF-β1/p53 signaling in renal fibrogenesis.

Authors:  Stephen P Higgins; Yi Tang; Craig E Higgins; Badar Mian; Wenzheng Zhang; Ralf-Peter Czekay; Rohan Samarakoon; David J Conti; Paul J Higgins
Journal:  Cell Signal       Date:  2017-11-28       Impact factor: 4.315

8.  Targeted Next-Generation Sequencing Identifies Pathogenic Variants in Diabetic Kidney Disease.

Authors:  Jose Lazaro-Guevara; Julio Fierro-Morales; A Hunter Wright; River Gunville; Christopher Simeone; Scott G Frodsham; Melissa H Pezzolesi; Courtney A Zaffino; Laith Al-Rabadi; Nirupama Ramkumar; Marcus G Pezzolesi
Journal:  Am J Nephrol       Date:  2021-03-26       Impact factor: 3.754

9.  MDM2 Contributes to High Glucose-Induced Glomerular Mesangial Cell Proliferation and Extracellular Matrix Accumulation via Notch1.

Authors:  Chun-Tao Lei; Hui Tang; Chen Ye; Chao-Qun You; Jiao Zhang; Chun-Yun Zhang; Wei Xiong; Hua Su; Chun Zhang
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

10.  Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept.

Authors:  Zhengtao Qin; Carl K Hoh; Emilia S Olson; Amin Haghighat Jahromi; David J Hall; Christopher V Barback; Young-Hyun You; Motoko Yanagita; Kumar Sharma; David R Vera
Journal:  J Nucl Med       Date:  2019-02-22       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.